Obesity Treatment
The latest news about Obesity Treatment: headlines, AI summaries and the full story from every source.
- Eli Lilly's Foundayo Obesity Pill Shows Significant Reduction in Sleep Apnea Severity
- Wave Life Sciences Reports Strong Q3 2026 Results with Robust Cash Position and Clinical Progress
- Novo Nordisk Raises Full-Year Guidance Following Strong Q3 Patient Growth and Pipeline Progress
- OAC Urges Cigna to Reconsider Decision on GLP-1 Medication Coverage for Weight Management
- Eli Lilly's New Weight Loss Drug Shows Significant Results in Clinical Trial
- Eli Lilly Reports Positive Mid-Stage Trial Results for EloraTZP Weight Loss Combination
- Eli Lilly Reports Improved Weight Loss with Combination Obesity Treatment in Mid-Stage Trial
- AbbVie's investigational obesity drug shows up to 9.8% weight loss in Phase 1 trial
- Patients Switching to Oral Wegovy Continue Weight Loss in Real-World Study
- Nanexa's Stock Surges Over 150% Following Licensing Deal with Novo Nordisk
- Novo Nordisk Reports Better Weight Loss Results for Experimental Obesity Drug CagriSema Compared to Eli Lilly’s Zepbound
- Novo Nordisk Reports Positive Semaglutide Trial Results for Obesity Treatment in Children
- Viking Therapeutics Advances Phase III Trials for VK2735 in Obesity
- Novo Nordisk Receives European Approval for Wegovy Pill as First Oral GLP-1 Therapy
- Fractyl Health Shares Rise After Positive Data for Revita Procedure
- Vivani Medical Developing GLP-1 Implant for Long-Term Weight Loss Maintenance
- Kailera Therapeutics Reports Positive Phase 3 Trial Results for Obesity Treatment
- Novo Nordisk and Eli Lilly Compete in GLP-1 Pill Market Ahead of Medicare Coverage
- Lilly's Obesity Medicines Gaining Wider Insurance Coverage in the U.S.
- Eli Lilly Announces Positive Phase 3 Results for Obesity Treatment Retatrutide
- Novo Nordisk Receives EU Approval for Higher-Dose Wegovy in Single-Dose Pen
- Eli Lilly's Next-Gen Obesity Drug Shows Significant Weight Loss in Late-Stage Trials
- Eli Lilly Reports Late-Stage Weight Loss Trial Results for Foundayo and Zepbound
- Novo Nordisk's Wegovy Pill Boosts GLP-1 Market, Challenges Eli Lilly's Position
- Kailera Therapeutics Completes $625 Million IPO, Largest in Biotech History
- Eli Lilly's Obesity Pill Shows Cardiovascular Risk Reduction in Late-Stage Trial